Octreotide

Overview

Octreotide is a synthetic octapeptide analog of somatostatin (somatotropin release-inhibiting factor, SRIF) developed by Sandoz (now Novartis) and approved by the FDA in 1988. It was the first somatostatin analog to achieve widespread clinical use, addressing the severe pharmacokinetic limitations of native somatostatin — a 14-amino-acid cyclic peptide with a plasma half-life of approximately 2-3 minutes that is impractical for therapeutic application.

Octreotide is marketed as:

• Sandostatin — immediate-release subcutaneous injection (50 mcg, 100 mcg, 200 mcg, 500 mcg, 1000 mcg)
• Sandostatin LAR — long-acting release intramuscular depot formulation (10 mg, 20 mg, 30 mg monthly)

The compound's primary clinical applications include:

• Treatment of acromegaly (excess growth hormone secretion)
• Symptomatic control of carcinoid syndrome (flushing, diarrhea from metastatic neuroendocrine tumors)
• Treatment of vasoactive intestinal peptide-secreting tumors (VIPomas)
• Acute management of esophageal variceal bleeding
• Various off-label uses in neuroendocrine and gastrointestinal disorders

Octreotide binds preferentially to somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5), which are the predominant subtypes mediating growth hormone and gastrointestinal hormone suppression. By contrast, it has low affinity for SSTR1, SSTR3, and SSTR4.

Structure and Sequence

Octreotide sequence: D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol

• Molecular formula: C₄₉H₆₆N₁₀O₁₀S₂
• Molecular weight: approximately 1,019.3 g/mol
• Key structural features:
  • Cyclic octapeptide: Disulfide bridge between Cys2 and Cys7 creates a constrained ring structure
  • D-amino acids: D-Phe at position 1 and D-Trp at position 4 confer resistance to enzymatic degradation
  • C-terminal threoninol: The reduced threonine alcohol at position 8 further enhances metabolic stability
  • Pharmacophore conservation: The Phe-D-Trp-Lys-Thr tetrapeptide core corresponds to the active site of native somatostatin (residues 7-10 of somatostatin-14), retaining the essential beta-turn conformation

Design rationale: Native somatostatin-14 (Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys) contains a biologically active beta-turn at positions 7-10. Octreotide was designed to retain this pharmacophore while dramatically improving metabolic stability through:

• Shortening the peptide from 14 to 8 amino acids
• Incorporating D-amino acids at strategic positions
• Adding the C-terminal alcohol modification
• These modifications extend the half-life from approximately 2 minutes to approximately 90-120 minutes

Mechanism of Action

Somatostatin Receptor Activation

Octreotide acts as an agonist at somatostatin receptors (SSTRs), a family of five G-protein coupled receptors that signal primarily through Gi/Go proteins:

Receptor Selectivity Profile:

• SSTR2: High affinity (primary therapeutic target) — mediates GH suppression, antisecretory effects, and antiproliferative effects on neuroendocrine cells
• SSTR5: Moderate affinity — contributes to GH and insulin suppression
• SSTR3: Low affinity
• SSTR1 and SSTR4: Minimal affinity

Endocrine Effects:

• Suppression of growth hormone (GH) secretion from pituitary somatotroph adenomas — the basis for acromegaly treatment
• Suppression of insulin-like growth factor 1 (IGF-1) levels secondarily through GH reduction
• Inhibition of insulin and glucagon secretion from pancreatic islets (primarily via SSTR5 and SSTR2 respectively)
• Suppression of thyroid-stimulating hormone (TSH) secretion

Gastrointestinal Effects:

• Inhibition of gastric acid, pepsin, and pancreatic enzyme secretion
• Reduced splanchnic blood flow and portal venous pressure (mechanism for variceal bleeding management)
• Inhibition of secretion from neuroendocrine tumor cells (serotonin, VIP, gastrin, motilin, secretin)
• Slowed gastrointestinal motility and reduced gallbladder contractility

Antiproliferative Effects:

• Direct cell cycle arrest via SSTR2-mediated activation of phosphotyrosine phosphatases
• Indirect antitumor effects through suppression of growth factors (GH, IGF-1, VEGF)
• Induction of apoptosis in some neuroendocrine tumor types

Research Summary

Pharmacokinetics

• Half-life: Approximately 90-120 minutes (subcutaneous); Sandostatin LAR maintains therapeutic levels for approximately 28 days
• Bioavailability: Approximately 100% (subcutaneous)
• Time to peak: Approximately 30 minutes (subcutaneous); 2-4 weeks for LAR depot
• Protein binding: Approximately 65%, primarily to lipoproteins
• Volume of distribution: Approximately 13.6 liters
• Metabolism: Hepatic, primarily through peptide bond hydrolysis
• Elimination: Approximately 32% excreted unchanged in urine; renal clearance accounts for a substantial portion
• Dose adjustments: Hepatic impairment (especially cirrhosis) requires dose reduction; renal impairment generally does not require adjustment
• LAR formulation: Microsphere depot technology using a biodegradable glucose star polymer matrix; requires intramuscular gluteal injection by healthcare professionals

Common Discussion Topics

Gallstone formation: Octreotide reduces gallbladder motility and bile composition, leading to cholelithiasis (gallstones) in approximately 15-30% of patients on long-term therapy. Ultrasound monitoring of the gallbladder is recommended. Most octreotide-associated gallstones are asymptomatic.

Relationship to growth hormone secretagogues: Octreotide functionally opposes the effects of growth hormone-releasing peptides such as GHRP-6, GHRP-2, ipamorelin, and sermorelin. Where these peptides stimulate GH secretion, octreotide suppresses it. This pharmacological opposition reflects the physiological balance between GHRH/ghrelin stimulation and somatostatin inhibition of GH release.

Theranostic applications: Octreotide's receptor binding has been adapted for both diagnostic imaging (OctreoScan with In-111 pentetreotide; Ga-68 DOTATATE PET/CT) and targeted therapy (Lu-177 DOTATATE, marketed as Lutathera). This "theranostic" paradigm — using the same receptor-targeting molecule for both diagnosis and treatment — exemplifies personalized medicine in neuroendocrine oncology.

Glucose metabolism effects: By suppressing insulin secretion, octreotide can impair glucose tolerance and occasionally precipitate hyperglycemia. Conversely, by also suppressing glucagon, some patients experience hypoglycemia. Blood glucose monitoring is recommended during initiation and dose adjustments.

Second-generation analogs: Lanreotide (Somatuline) and pasireotide (Signifor) are alternative somatostatin analogs. Lanreotide has a similar SSTR2-preferring profile to octreotide but is formulated as a deep subcutaneous depot. Pasireotide has broader receptor affinity (including SSTR1, 3, and 5) and is used for Cushing disease and acromegaly refractory to octreotide.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Always consult a qualified healthcare professional.

Transition from SC to LAR: Patients stabilized on subcutaneous octreotide should continue SC injections for at least 2 weeks after the first LAR injection to maintain therapeutic levels during the LAR onset period. Monitor for gallstone development with long-term use.

Related Compounds

• Ghrelin — endogenous GH secretagogue whose effects are functionally opposed by somatostatin signaling
• Sermorelin — GHRH analog that stimulates GH release, counteracted by somatostatin/octreotide
• Ipamorelin — selective GH secretagogue acting through GHS-R1a
• IGF-1 LR3 — downstream effector of GH signaling that octreotide indirectly suppresses